Concepedia

Publication | Closed Access

Economic evaluation of new targeted therapies for the first‐line treatment of patients with metastatic renal cell carcinoma

DOI

45

Citations

14

References

2011

Year

Ágnes Benedict, Robert A. Figlin, Per Sandström, Ulrika Harmenberg, Anders Ullén, Claudie Charbonneau, Rickard Sandin, Edit Remák, Hariharan Subramanian, Sylvie Négrier
British Journal of Urology

Abstract

• The present analyses suggest that first-line mRCC treatment with sunitinib is a cost-effective alternative to sorafenib and bevacizumab plus IFN-α.

References

YearCitations

Page 1